GPR15 and colonic neoplasm: Our current findings that the T cell homing receptor, GPR15 can augment the infiltration of tumor-fighting effector T cells and alter the TME in colon cancer lesions in pre-clinical models hold therapeutic promise in immunotherapy-based tumor eradication using GPR15 agonists and improving patient survival.